The resolution of hyperglycemia is associated with suppression of in-hospital cardiac complications in patients with acute coronary syndromes (ACS). This study evaluated carotid artery plaque echolucency using ultrasound in patients with ACS and type 2 diabetes mellitus (DM) to determine whether acarbose, an α-glucosidase inhibitor, may rapidly stabilize unstable atherosclerotic plaques.
yperglycemia is associated with an increased risk of in-hospital death and cardiac complications in patients with acute myocardial infarction (AMI) and with or without known diabetes mellitus (DM). 1-5 Previous reports 4-6 have suggested that hyperglycemia is associated with microvascular dysfunction, vascular inflammation, a prothrombotic state, endothelial dysfunction and impaired myocardial glucose use, all of which potentially worsen myocardial ischemia. The rapid resolution of hyperglycemia is associated with early improvement of in-hospital cardiac complications in patients with AMI. 4,5,7-9 It is known that rupture or instability of plaques rich in lipid and inflammatory cells importantly contribute to occlusive vascular events. 10 However, it remains unknown whether vulnerable coronary plaques may be rapidly stabilized in parallel with early blood glucose lowering to reduce cardiac events in patients with acute coronary syndromes (ACS) and hyperglycemia.
Recent studies 10-12 support the concept that plaque instability is not merely a local vascular occurrence, but rather that plaque instability exists simultaneously at multiple sites in the systemic vascular bed. Thus, it is possible that coronary plaque vulnerability may be assessed by evaluating plaque characteristics in other vessels such as the carotid arteries. We and others have assessed the composition of carotid plaques using ultrasound with integrated backscatter (IBS) analysis. [13] [14] [15] [16] [17] Fibrosis and calcification in the carotid plaque give a high IBS value, whereas macrophage-rich lesions and lipid deposition give a low IBS value. 16- 19 We have shown that ultrasound evaluation of plaque echolucency is useful for monitoring the efficacy of therapy using statins or thiazolidinediones on atheroma vulnerability in carotid plaques [13] [14] [15] and that carotid plaque echolucency is associated with vulnerable coronary plaques. 15 Acarbose, an α-glucosidase inhibitor, is an oral antidiabetic agent that has been shown to be as efficacious as other commonly used antidiabetic agents. [20] [21] [22] [23] Given that acarbose has a relatively modest efficacy of blood glucose lowering and minimal drug-drug interactions, 23 it rarely induces severe hypoglycemic episodes when used in combination with other antidiabetic medications. Acarbose may be useful for glucose management in AMI patients with known type 2 DM, because management of glucose levels within a given range and with minimal risk of hypoglycemia is recommended for the treat-H 1453 Carotid Plaque Echogenicity and Acarbose in ACS ment of hyperglycemia in patients with AMI. 24 Acarbose directly targets postprandial hyperglycemia, 23 which has been identified as an important cardiovascular risk factor. 25 Unlike acarbose, other antidiabetic medications, such as sulfonylureas, have a greater effect on fasting hyperglycemia than on postprandial hyperglycemia. 26 Thus, the goal of the study was to determine whether acarbose treatment in patients with ACS and type 2 DM might have an early benefit in stabilizing unstable carotid plaques. Carotid ultrasound was used to examine the echolucency of carotid arterial plaques as an index of plaque vulnerability.
Methods

Study Patients
This study enrolled 44 patients (mean age 65±11 years, range 43-79 years, 35 males) from 112 consecutive patients with ACS who were admitted to Yamanashi University Hospital from December 2008 to April 2010. The inclusion criteria included previously known type 2 DM and the presence of carotid intima-media thickness (IMT) ≥1.1 mm with protrusion of the vessel wall into the lumen. 27 Patients with severe carotid stenosis (≥50%) were excluded because they have a high risk of ischemic stroke. Type 2 DM was defined according to the criteria of the American Diabetic Association. 28 ACS was diagnosed by the presence of acute ischemic symptoms lasting ≥20 min within 48 h before admission to hospital, and electrocardiographic changes consistent with ACS. 29 AMI was diagnosed when creatine kinase-MB levels increased to at least twice the upper limit of normal or when troponin T levels were >0.1 ng/ml. Patients without AMI were considered to have unstable angina pectoris. All of the patients with ACS had successful reperfusion therapy with percutaneous coronary intervention immediately after admission to Yamanashi University Hospital. Exclusion criteria were as follows: (1) use of α-glucosidase inhibitor during the preceding 6 months, (2) history of hepatic disease, (3) chronic renal dysfunction (serum creatinine level >2.0 mg/dl), (4) major surgery and trauma or serious infectious disease within the previous 4 weeks, (5) history of hypersensitivity to acarbose, (6) cardiogenic shock or pulmonary edema (Killip classification ≥II or Forrester classification ≥II) at admission, (7) low left ventricular ejection fraction on echocardiography (<40%), or (8) stroke at admission.
The present study also included 50 patients with stable coronary artery disease (CAD), carotid plaque (IMT ≥1.1 mm) and type 2 DM. None of the patients with stable CAD had had any episodes of angina at rest and no changes in the frequency of angina in the previous year. These patients with stable CAD were selected to match the traditional risk factors for atherosclerosis of the patients with ACS, and they were examined to compare biomarkers and carotid ultrasound parameters at baseline with the ACS patients. The baseline clinical characteristics and medication usage are shown in Tables 1 and 2, respectively. All female patients were postmenopausal, and not on any hormone replacement therapy. Written informed consent was given by all patients before the study. This study was approved by the institution's ethics committee. The investigation conformed to the principles outlined in the 1975 Declaration of Helsinki. 
Study Protocol
The study patients with ACS were all treated with standard medical therapy and were randomly allocated, using random numbers generated by a computer, into a group treated with acarbose (n=22) or a control group that was treated without acarbose (n=22). Acarbose treatment was initiated within 5 days after the onset of ACS. Patients in both groups were prospectively followed for 6 months. The daily dose of acarbose was initially 150 mg, and the dose was increased to 300 mg at 2 months after the start of treatment when the hemoglobin A1c (HbA1c) level was ≥7.5% 2 months after enrollment. Antidiabetic medications other than α-glucosidase inhibitor were permitted in both groups, but the types of antidiabetic medications were maintained throughout the study after the allocation of acarbose. In the control group, the increase in the dosage of the antidiabetic medications was permitted when the HbA1c level was ≥7.5% 2 months after enrollment. Carotid ultrasound and blood sampling were performed on the morning after an overnight fast in the same manner before, and at 2 weeks, 1 month and 6 months of treatment. All patients received the standardized cardiac medications shown in Table 2 during the follow-up period.
Carotid Ultrasound
A carotid ultrasound examination was performed in the ultra-sound laboratory using an 11.0-MHz, linear-array transducer (SONOS-5500, Phillips, Andover, MA, USA) in the morning after an overnight fast before treatment; and after 2 weeks, 1 month and 6 months of treatment. [13] [14] [15] The measurements were performed by 2 well-trained researchers (J.O., T.N.) who did not have any information about the randomization or clinical characteristics of the study patients. IMT was defined as the distance from the leading edge of the lumen-intima interface to the leading edge of the media-adventia interface on a longitudinal image of each carotid artery. Atherosclerotic plaque was defined as a lesion with a focal IMT ≥1.1 mm, which resulted in a localized protrusion of the vessel wall into the lumen. Maximal IMT (IMTmax) was defined as the greatest axial thickness in the carotid arteries. Subsequently, we measured the IBS value of all plaques, as described previously. [13] [14] [15] For each plaque, conventional high resolution, B-mode images were obtained, followed by the acquisition of 60 IBS images. Atherosclerotic plaques were analyzed using the manual definition mode to outline the region of interest (ROI). The average power of the IBS signal within the ROI was measured and displayed in decibels for a total of 60 frames. In the case of heterogeneous plaques, we excluded excessively high echogenic areas with acoustic shadowing, which indicated calcification in the ROI. We adopted the adventitia as the reference object and then expressed the relative IBS value of the intimamedia complex as the difference in IBS values between the intima-media and adventitia (calibrated IBS=intima-media IBS value -adventitia IBS value). In each patient, we selected the plaque with the most echolucent calibrated IBS value among all carotid plaques at baseline as the target plaque for monitoring the calibrated IBS value during treatment. The exact distance of the target plaque from the bifurcation of the common carotid artery or a site of arterial calcification was recorded as a landmark in each patient to ensure that the same target plaque was measured during treatment. Also, the head positions and probe positions during the examinations were recorded in each patient. Measurement of IMTmax and calibrated IBS was performed twice during each session in all patients, and the averaged value of the 2 measurements was used for further analyses. The inter-and intraobserver variabilities for repeated measurements of the calibrated IBS value were 0.3±0.3 dB and 0.5±0.4 dB, respectively. An increase in IBS value reflects an increase in carotid plaque echogenicity.
Laboratory Examinations
Venous blood samples were obtained from all patients after a 12-h overnight fast at the same time points used for the ultrasound assessment of carotid plaques. After the blood sampling and ultrasound examination in the fasting condition, all study patients had the same test breakfast (500 kcal) consisting of 75 g carbohydrate, 24 g protein and 12 g fat, supplied by the hospital. At 2 h after taking the test meal, blood samples were again obtained for measurement of postprandial glucose levels. High sensitive C-reactive protein (CRP) levels in the fasting plasma were assayed by rate nephelometry (Dade Behring, Marburg, Germany). The serum total cholesterol and triglyceride concentrations were measured enzymatically, and the serum high-density lipoprotein cholesterol (HDL-C) concentration was measured by heparin-Ca 2+ /Ni 2+ precipitation. Lowdensity lipoprotein cholesterol levels were calculated by the Friedewald's formula. Plasma insulin levels (immunoreactive insulin; IRI) were determined by an enzyme immunoassay (Tosoh, Tokyo, Japan). The plasma glucose concentration was determined with an autoanalyzer using the glucose oxidase method. The homeostasis model assessment of insulin resis- Values are expressed as number of patients (%). ACS, acute coronary syndrome; CCB, calcium-channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; SU, sulfonylurea. Carotid Plaque Echogenicity and Acarbose in ACS tance (HOMA-IR) was determined by the following formula: fasting plasma insulin (in μU/ml)×fasting plasma glucose (in mg/dl)/405. Plasma IRI levels and HOMA-IR were measured for the statistical analysis in the study patients taking no insulin treatment.
Statistical Analysis
Data are expressed as the mean value ± SD, median and interquartile range (25 th and 75 th percentiles) or frequencies (%).
The Shapiro-Wilk test showed that the levels of CRP, triglycerides, IRI and HOMA-IR were not distributed normally, and therefore these data were log-transformed for statistical analysis. The mean value and frequency between 2 groups were compared using a Student's unpaired t-test and a chi-square analysis, respectively. For comparisons of the mean values before and during treatment, 1-way analysis of variance (ANOVA) was performed followed by a Scheffé test for post-hoc comparisons. The mean value of lipids, other biochemical parameters and calibrated IBS values before and during treatment were compared between 2 groups using 2-way ANOVA for repeated measures followed by post-hoc testing. P values were tabulated for duration, group (acarbose vs. control) effects and interaction by 2-way repeated-measures ANOVA. When the duration effect was significant, differences between time points in each group were compared with a Scheffé test. When the group effect was significant, differences between groups at each time point were compared with a Student's unpaired t-test. Also, the percent changes in HbA1c and CRP from baseline to either 1 month or 6 months of treatment were not distributed normally, and therefore the relationship of the percent changes in calibrated IBS values with the percent changes in CRP and other biochemical parameters after therapy was analyzed by the Spearman rank correlation test using data from both treatment groups. The independent relationship of the percent changes in calculated IBS with those in the biochemical parameters was examined in the multivariate linear regression analysis using the percent changes in biochemical parameters as covariates that had a significant relationship with the change in calculated IBS at 6 months treatment in the Spearman rank correlation test. Statistical significance was defined as P<0.05. Analyses were performed using StatView 5.0 for Windows (Tokyo, Japan) and JMP (SAS Institute Inc, Cary, NC, USA). Previous literature showed that acarbose treatment may potentially improve HOMA-IR by 20-30% in patients with type 2 DM. 30 On the basis of the correlation between changes in HOMA-IR and calibrated IBS value in our previous study, 13 we proposed that acarbose would increase the calibrated IBS value by approximately 25% after 6 months of treatment. Power analysis showed that given this effect size (25%), a probability of type-I error of 0.05 (2-tailed), a power of 0.8, and an expected SD of the calibrated IBS values of 2.0 dB, the minimum required sample size needed was 20 patients in each group.
Results
Comparison of Pretreatment Data in Patients With ACS
The daily dose of acarbose was increased to 300 mg at 2 months after the start of treatment in 10 patients in the acarbose group, and the dose remained at 150 mg during the 6 months of treatment in the remaining 12 patients. All of the study patients completed the trial, and there were no adverse events related to acarbose. None of the study patients had recurrent cardiovascular events or obvious heart failure during the 6 months of follow-up. The blood glucose levels at admission were similar between the acarbose and control groups ( Table 1 ). The 2 treatment groups had similar profiles for traditional risk factors, calibrated IBS values, IMTmax, and levels of CRP and fasting and postprandial glucose that were collected on the day after admission ( Table 1 ). Both treatment groups had hyperglycemia in the fasting and postprandial conditions ( Table 1) . The use of antihypertensive, lipid-lowering, antiplatelet and antidiabetic medications, except acarbose at administration and at 6 months of the follow-up, was similar between the 2 groups ( Table 2) .
Effects of Treatment on Parameters of Carotid Plaque in Patients With ACS During the 6 Months of Follow-up
The calibrated IBS value of echolucent carotid plaques in the acarbose group showed a statistically significant increase at 1 month of treatment (Figure 1) . The calibrated IBS value showed further increase from 1 to 6 months of treatment with acarbose (Figure 1) . The calibrated IBS value after 6 months of acarbose therapy was similar to that in patients with stable CAD (Figure 1) . Representative IBS images of carotid atheroma from pretreatment to 6 months of treatment with acarbose are shown in Figure 2 . In contrast, the calibrated IBS value in the control group showed a statistically significant increase at 6 months of treatment, but remained lower compared with that in patients with stable CAD (Figure 1) . The increase in the IBS value was significantly greater in the acarbose group than that in the control group, using 2-way ANOVA for repeated measures. The IMTmax was not significantly changed after 6 months of treatment in either group (Figure 1) .
Effects of Treatment on Biochemical and Metabolic Parameters in Patients With ACS During the 6 Months of Follow-up
All laboratory parameters, except triglyceride and HDL-C levels, were significantly decreased during the 6-month follow-up period in both groups ( Table 3) . Postprandial glucose levels and CRP levels at 1 and 6 months were significantly lower in the acarbose group than in the control group ( Table 3) .
Correlations of Changes From Baseline in Calibrated IBS Values With Those in Biochemical and Metabolic Parameters in Patients With ACS
In the Spearman rank correlation test, the percent change in the calibrated IBS value from baseline to 6 months was associated with the percent change in HDL-C (ρ=0.34), HOMA-IR (ρ=−0.32), postprandial glucose levels (ρ=−0.35) and CRP levels (ρ=−0.36) from baseline to 6 months, but not fasting glucose levels ( Table 4 ). Multiple linear regression analysis showed a significant correlation of the percent change in the calibrated IBS value with the changes in postprandial glucose levels and CRP levels from baseline to 6 months, which was independent of the changes in HDL-C and HOMA-IR ( Table 5 ).
Discussion
The present study showed that acarbose increased carotid plaque echogenicity within the first month of therapy in patients with ACS. Moreover, acarbose showed a further increase in the calibrated IBS value of carotid plaques from 1 to 6 months of treatment. These results indicate that an improvement in carotid plaque echolucency occurs within 1 month of acarbose treatment, and continues during the next 5 months. In contrast, the improvement in plaque echolucency was minimal during the 6 months of follow-up in the control group. These results suggest that early treatment of hyperglycemia with acarbose may potentially stabilize vulnerable carotid plaques in ACS patients with type 2 DM. The results are con- Several mechanisms for the improvement in carotid echolucency by acarbose treatment may be considered. Although both postprandial hyperglycemia and fasting hyperglycemia were improved in the control groups as well as the acarbose group, the improvement in postprandial hyperglycemia was more rapid and greater in the acarbose group than in the control group. This is attributed to acarbose treatment because acarbose has been shown to reduce postprandial hyperglycemia to a greater extent than other oral antidiabetic agents such as sulfonylureas. 23 It has been shown that the circulating levels of pro-inflammatory cytokines and CRP are increased in patients with type 2 DM, but these levels are more greatly associated with post-challenge hyperglycemia than fasting hyperglycemia. 31, 32 We and others have shown that postprandial hyperglycemia induces oxidative stress and endothelial dysfunction. 4,5, 33 Postprandial hyperglycemia could induce proinflammatory cytokines through oxidative stress-induced activation of nuclear factor kappa B. 4, 5 In line with those previous reports, the present study showed that the decrease in CRP levels was greater in the acarbose group than in the control group. Thus, an improvement in postprandial hyperglycemia may lead to a decrease in CRP levels after acarbose treatment. Moreover, the present results showed that an improvement in carotid echolucency was associated with reduction in both postprandial hyperglycemia and CRP levels at 6 months. Therefore, suppression of the inflammatory response after acarbose treatment may at least partly contribute to the improved echolucency of carotid plaques in the present study on the basis of the inflammatory features of unstable atherosclerotic plaque. At 1 month of treatment, there was not a statistically significant association between the improvement in carotid echolucency and CRP reduction. However, CRP levels at 1 month were reduced more greatly in the acarbose group than in the control group. Thus, the antiinflammatory effect of acarbose may also play a possible role in the improved carotid echolucency in the acarbose group at 1 month, although other medications, including statin and angiotensin II receptor blockers (ARB) added after enrollment, could potentially contribute to the improvement in carotid echolucency. It has been shown that exposure of the lower small intestine to undigested carbohydrate after acarbose leads to an increase in the release of glucagon-like peptide-1 (GLP-1), 34 which is known to have antiatherosclerotic effects. 35 This may be another potential mechanism for the beneficial effects of acarbose treatment, although the present study did not measure GLP-1 levels.
The present study showed that IMTmax did not significantly regress during 6 months of therapy with acarbose. These data suggest that plaque stabilization may precede regression in plaque size and support the concept 10,36 that stabilization rather than regression of vulnerable atheroma is more important in the early reduction of coronary events. A previous report 37 showed that acarbose delayed progression of IMT during treatment for more than 1 year, which is not consistent with the present data. The relatively short period of treatment with acarbose may partly explain the lack of suppression of IMTmax in the present study.
Study Limitations
First, this study included a relatively small number of patients, which limited the statistical power of the analysis to show small differences between groups. Second, the study included patients with carotid plaque with a maximum IMT ≥1.1 mm, 27 but patients with carotid stenosis ≥50% were excluded because of a high risk of ischemic stroke. It remains to be determined whether similar results would be obtained in general patients with AMI. Third, the largest plaque was selected for serial measurement of IBS from among the eligible plaques (≥1.1 mm of IMT) in each patient. It has been shown that plaque progression is affected by shear stress; low shear causes plaque progression at the proximal internal carotid and the bifurcation of the carotid artery. 38 Thus, plaque location may have a potential influence on the change in IMTmax and IBS values over the 6 months of follow-up. Fourth, antiplatelet and antihypertensive drugs, including angiotensin-converting enzyme inhibitors, ARB, statins, and calcium-channel blockers, may contribute to favorable change in carotid plaque echolu- Data are expressed as Spearman's correlation coefficient by rank (ρ ). The data are from patients including the acarbose treatment group and the control group. IBS, integrated backscatter. Other abbreviations see in Table 1 . Data are expressed as standardized regression coefficient (β). Clinical parameters were selected as independent variables because they had a significant relation with the % change in calibrated IBS values in the Spearman's correlation test in Table 4 . The data are from patients including the acarbose treatment group and the control group. Abbreviations see in Tables 1,4 . Carotid Plaque Echogenicity and Acarbose in ACS cency, 39,40 although there was no significant difference in the number of patients given these drugs at baseline and also at 6 months of the follow-up between both groups.
Conclusions
Acarbose rapidly improved carotid plaque echolucency within 1 month of therapy initiation in patients with ACS and type 2 DM. This may reflect the early clinical benefits of treatment of hyperglycemia in patients with ACS. However, the present results are preliminary and should be confirmed by further studies with a larger number of study patients.
